IPO registrations (S-1, F-1) · Registrants
OnKure Therapeutics, Inc.
- SEC CIK
- 1637715 · filings on EDGAR ↗
- Former names
- Reneo Pharmaceuticals, Inc. (2018–2024)
- Registration
- Form S-1, first filed 2021-03-19, last 2024-10-23; 2 initial registrations, 1 amendment
- Outcome
- Final prospectus filed 2021-04-09; declared effective 2021-04-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, Boulder, CO 80301
- EIN
- 47-2309515
- Ticker
- OKUR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- OnKure Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2021-04-05)
- Final price
- $15.00 per share, within the range (424B4 filed 2021-04-09, an initial public offering)
- Shares sold
- 6,250,000
- Gross proceeds
- $93,750,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol RPHM
- Lead underwriters
- Jefferies; Leerink Partners (2,187,500 shares); Piper Sandler (1,718,750 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: OnKure Therapeutics, Inc. Fuzzy (name and state)
- Business registration: ONKURE THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: RENEO PHARMACEUTICALS INC EXACT (EIN (EXACT))
- Form D issuer: OnKure Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: OnKure Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Eric M Dube Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-03-19 | S-1 | S-1 (registration) | Reneo Pharmaceuticals, Inc. | 0001193125-21-087741 ↗ |
| 2021-04-05 | S-1/A | S-1/A (amendment) | Reneo Pharmaceuticals, Inc. | 0001193125-21-105697 ↗ |
| 2021-04-08 | EFFECT | EFFECT (declared effective) | Reneo Pharmaceuticals, Inc. | 9999999995-21-001364 ↗ |
| 2021-04-09 | 424B4 | 424B4 (final prospectus) | Reneo Pharmaceuticals, Inc. | 0001193125-21-111652 ↗ |
| 2022-05-09 | EFFECT | EFFECT (declared effective) | Reneo Pharmaceuticals, Inc. | 9999999995-22-001381 ↗ |
| 2023-06-13 | EFFECT | EFFECT (declared effective) | Reneo Pharmaceuticals, Inc. | 9999999995-23-001742 ↗ |
| 2023-11-21 | EFFECT | EFFECT (declared effective) | Reneo Pharmaceuticals, Inc. | 9999999995-23-003413 ↗ |
| 2024-08-26 | EFFECT | EFFECT (declared effective) | Reneo Pharmaceuticals, Inc. | 9999999995-24-002630 ↗ |
| 2024-10-23 | S-1 | S-1 (registration) | OnKure Therapeutics, Inc. | 0001193125-24-241926 ↗ |
| 2024-10-30 | EFFECT | EFFECT (declared effective) | OnKure Therapeutics, Inc. | 9999999995-24-003323 ↗ |
| 2025-03-21 | EFFECT | EFFECT (declared effective) | OnKure Therapeutics, Inc. | 9999999995-25-000731 ↗ |
| 2025-11-18 | EFFECT | EFFECT (declared effective) | OnKure Therapeutics, Inc. | 9999999995-25-003308 ↗ |
| 2026-05-04 | EFFECT | EFFECT (declared effective) | OnKure Therapeutics, Inc. | 9999999995-26-001477 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-05 | S-1/A | registration statement | $15.00–$17.00 | 6,250,000 | - | Nasdaq RPHM | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2021-04-09 | 424B4 | final prospectus | $15.00 | 6,250,000 | $93,750,000 | Nasdaq RPHM | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BASKETT FOREST | TenPercentOwner | 2 | 2021 | ||
| Cardon Lon | Director | 2 | 2021 | ||
| Cruse Michael | Officer | Chief Operating Officer; Senior VP, Corporate Operation; Senior VP-Corporate Operations | 7 | 2021–2022 | |
| Dorenbaum Alejandro | Officer | Chief Medical Officer | 3 | 2021–2022 | |
| Dube Eric M | Director | 3 | 2021–2023 | person page Fuzzy | |
| FLESHER GREGORY J. | Director,Officer | President and CEO | 4 | 2021–2022 | |
| Florence Anthony A. Jr. | TenPercentOwner | 2 | 2021 | ||
| GREY MICHAEL G | Director; Director,Officer | Executive Chairman | 12 | 2021–2026 | |
| Harrison Kenneth Ph.D. | Director | 3 | 2021 | ||
| Jindal Vineet R. | Officer | Chief Financial Officer | 3 | 2021 | |
| Johnson Wendy S. | Officer | Chief Development Officer | 3 | 2021 | |
| Kordel Johan | Director | 1 | 2021 | ||
| Makhzoumi Mohamad | TenPercentOwner | 2 | 2021 | ||
| MAKOWER JOSHUA | TenPercentOwner | 2 | 2021 | ||
| Mathers Edward T | Director | 12 | 2021–2026 | ||
| Muralidhar Bali | Director | 12 | 2021–2023 | ||
| NEA 15 GP, LLC | TenPercentOwner | 2 | 2021 | ||
| NEA Partners 15, L.P. | TenPercentOwner | 2 | 2021 | ||
| New Enterprise Associates 15, L.P. | TenPercentOwner | 2 | 2021 | ||
| Novo Holdings A/S | TenPercentOwner | 3 | 2021–2023 | ||
| O'Donnell Niall | Director | 6 | 2021–2023 | ||
| RiverVest Venture Fund III, L.P. | TenPercentOwner | 2 | 2021 | ||
| RiverVest Venture Fund III (Ohio), L.P. | TenPercentOwner | 2 | 2021 | ||
| RiverVest Venture Fund IV, L.P. | TenPercentOwner | 2 | 2021 | ||
| SANDELL SCOTT D | TenPercentOwner | 2 | 2021 | ||
| Seltzer Stacey Denenberg | Director | 4 | 2021–2023 | ||
| Sonsini Peter W. | TenPercentOwner | 2 | 2021 | ||
| Hall Ashley | Officer | Chief Development Officer | 4 | 2021–2023 | |
| Hoelscher Paul W. | Director | 4 | 2022–2023 | ||
| Lam Jennifer | Officer | VP of Finance & Administration | 2 | 2022 | |
| Blunt Roshawn A. | Director | 3 | 2022–2023 | ||
| Leonard Braden Michael | Other; TenPercentOwner | 7 | 2024 | ||
| Agresta Samuel | Officer | Chief Medical Officer | 5 | 2024–2026 | |
| Carruthers R Michael | Director | 5 | 2024–2026 | ||
| Hartley Dylan | Officer | Chief Scientific Officer | 5 | 2024–2026 | |
| Jansen Valerie Malyvanh | Director | 5 | 2024–2026 | ||
| Leverone Jason A. | Officer | Chief Financial Officer | 12 | 2024–2026 | |
| Manke Isaac | Director | 9 | 2024–2026 | ||
| Phillips Andrew John | Director | 5 | 2024–2026 | ||
| Saccomano Nicholas A | Director,Officer | President and CEO | 12 | 2024–2026 | |
| ACORN BIOVENTURES, L.P. | TenPercentOwner | 2 | 2024–2025 | ||
| ACORN CAPITAL ADVISORS GP, LLC | TenPercentOwner | 2 | 2024–2025 | ||
| Hove Anders D | TenPercentOwner | 2 | 2024–2025 | ||
| Chen Bihua | Other; TenPercentOwner | 3 | 2024–2025 | ||
| Cormorant Asset Management, LP | Other; TenPercentOwner | 3 | 2024–2025 | ||
| Cormorant Global Healthcare Master Fund, LP | Other; TenPercentOwner | 3 | 2024–2025 | ||
| Cormorant Private Healthcare Fund III LP | Other; TenPercentOwner | 3 | 2024–2025 | ||
| Cormorant Private Healthcare Fund IV LP | Other; TenPercentOwner | 3 | 2024–2025 | ||
| Cormorant Private Healthcare Fund V LP | Other; TenPercentOwner | 3 | 2024–2025 | ||
| ACORN BIOVENTURES 2, L.P. | TenPercentOwner | 1 | 2025 | ||
| Acorn Capital Advisors GP 2, LLC | TenPercentOwner | 1 | 2025 | ||
| Ratcliffe Liam | Director | 4 | 2026 | ||
| Access Industries Holdings LLC | TenPercentOwner | 1 | 2026 | ||
| ACCESS INDUSTRIES MANAGEMENT, LLC | TenPercentOwner | 1 | 2026 | ||
| AI Biotechnology LLC | TenPercentOwner | 1 | 2026 | ||
| Blavatnik Len | TenPercentOwner | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-10-21 | OnKure Therapeutics, Inc. | Pharmaceuticals | $65,000,000 | $65,000,000 | 20 | 1 |
| 2020-12-21 | Reneo Pharmaceuticals, Inc. | Pharmaceuticals | $94,769,998 | $47,384,999 | 15 | 1 |
| 2019-05-14 | Reneo Pharmaceuticals, Inc. | Pharmaceuticals | $25,000,002 | $25,000,002 | 9 | 1 |
| 2018-01-08 | Reneo Pharmaceuticals, Inc. | Pharmaceuticals | $51,994,684 | $21,994,682 | 16 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | OnKure Therapeutics, Inc. | State business registries | name and state | |
| Business registration | ONKURE THERAPEUTICS, INC. | State business registries | name and state | |
| Form 5500 plan sponsor | RENEO PHARMACEUTICALS INC | EIN (EXACT) | ||
| Form D issuer | OnKure Therapeutics, Inc. | Form D private offerings | CIK (EXACT) | |
| Person page | Eric M Dube | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| SEC filer | OnKure Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.